The Y-box binding protein, YB-1, belongs to a family of multifunctional proteins which regulate gene expression on both transcriptional and translational levels. The tumor suppressor gene p53 displays growth suppressive properties by regulating gene expression through transcriptional regulation. We now demonstrate that YB-1 directly interacts with p53 using an in vitro pull-down assay. Using immunochemical co-precipitation methods, we also found that the two proteins are bound in vivo. Deletion analysis showed that three independent domains of YB-1, one at the N-terminal and two at the Cterminal, interact with p53. Conversely, a 14 amino acid sequence at the C-terminal of p53 was required for its interaction with YB-1. Gel mobility shift assays showed that the interaction of YB-1 with p53 stimulated the sequence-speci®c DNA binding of p53 to its consensus sequence. By contrast, this interaction inhibited the binding of YB-1. Using a p53-responsive p21 promoter linked to a reporter gene, it can be shown that antisense expression of YB-1 inhibits the induction of this promoter by p53 in transient transfection assays. These ®ndings delineate a straightforward mechanism for gene expression through p53-YB-1 interaction. Oncogene (2000) 19, 6194 ± 6202.
Introduction
The human Y-box binding protein, YB-1, belongs to a Y-box protein family which is widely distributed from bacteria to mammals. Y-box proteins contain a cold-shock domain (CSD), which is highly conserved from prokaryotic cold-shock proteins, which function as RNA chaperones. Recent studies have demonstrated that eukaryotic Y-box proteins are multifunctional, recognizing double-and single-stranded DNA, and sequence-speci®c and non-speci®c RNA, thus regulating gene expression at both transcriptional and translational levels (Matsumoto and Wole, 1998; Sommerville, 1999) . Recent studies found that the rabbit Y-box protein, p50, is a major core protein of cytoplasmic messenger ribonucleoprotein particles (mRNP) in somatic cells; p50 seems to regulate translation through non-speci®cally interacting with mRNA (Evdokimova et al., 1998) . The murine Y-box protein, MSY1, was also reported to bind to single-stranded DNA and mRNA speci®cally and regulate both transcription and translation (Kelm et al., 1999) . Similar Y-box proteins from Xenopus (mRNP3/mRNP4) and mouse (MSY2) were found as mRNA masking proteins in germinal cells (Matsumoto et al., 1996; Gu et al., 1998; Herbert and Hecht, 1999) .
With regard to transcriptional control, YB-1 was initially reported to associate with the duplex Y-box sequence found in the major histocompatibility complex class II genes. It was hypothesized that YB-1 might have a role in promoting cell proliferation since Y-box elements were present in the promoters of several genes whose activity is associated with cell division; epidermal growth factor receptor, proliferating cell nuclear antigen, DNA polymerase, thymidine kinase, and topoisomerase IIa (Wole, 1994; Ladomery and Sommerville, 1995) . Recent studies revealed that YB-1 associates with RelA, YY-1 and Pura to modulate gene expression (Raj et al., 1996; Li et al., 1997; Safak et al., 1999) .
YB-1 is mainly localized in the cytoplasm and then accumulates in the nucleus when genotoxic stress occurs (Koike et al., 1997) . Nuclear localization of YB-1 has been reported to be associated with gene expression of its stress-inducible target genes (Bargou et al., 1997; Oda et al., 1998) , suggesting that YB-1 is a stress-activated protein. YB-1 also appears to protect cells from the cytotoxic eects that induce DNA damage (Ohga et al., 1996) . The YB-1 protein binds to apurinic DNA and cisplatin-modi®ed nucleotides with high anity, and the C-terminal region of YB-1 binds directly to proliferating cell nuclear antigen (Hasegawa et al., 1991; Lenz et al., 1990; Ise et al., 1999) . YB-1 may thus be involved in the process of DNA repair, possibly by interacting with other repairrelated proteins.
The tumor suppressor gene p53 displays its growth suppressive properties by transcriptional regulation of gene expression (Levine 1997) . Several genes which are transcriptionally controlled by p53 have been identi®ed to function downstream of p53 in the DNA damage response pathway: such genes contain p21/Waf1/Cip1 (El-Deiry et al., 1993) , GADD45 (Kastan et al., 1992) , cyclin G (Okamoto and Beach, 1994) , and bax (Miyashita and Reed, 1995) . By modulating the expression levels of these genes, p53 can induce either cell arrest or apoptosis under genotoxic stress through cell cycle checkpoints to ensure genetic stability. Another signi®cant role of p53 is its possible involvement in DNA repair. p53 preferably associates with damaged DNA (Bakalkin et al., 1994; Lee et al., 1995) and interacts with nucleotide excision repair factors such as XPB and XPD (Wang et al., 1995) .
The Y-box consensus sequence, an inverted CCAAT box, is located in the human multidrug resistance 1 (MDR1) gene promoter region (nt 782 to nt 773). This sequence is required for basal promoter activity as well as for promoter activation by various environmental stimuli, including carcinogens, anticancer agents, and UV irradiation (Uchiumi et al., 1993; Asakuno et al., 1994; Goldsmith et al., 1993; . We have reported that YB-1 binds to the Ybox on the MDR1 promoter and is directly involved in MDR1 gene activation by regulation of gene transcription . Chin et al. (1992) reported that a mutant p53 speci®cally stimulates the MDR1 promoter, whereas a wild-type p53 represses promoter activity. In addition, impaired p53-mediated transactivation and repression by trans-dominant negative p53 have been found to markedly elevate the levels of MDR mRNA and P-gp protein in both rodent hepatoma cells and human colon carcinoma cells (Thottassery et al., 1997) . These data on p53, together with our ®ndings on YB-1, suggest that expression of MDR1 gene is regulated through the mutual interaction of p53 and YB-1.
We examined the possible association between YB-1 and p53 proteins based on the following three points: (1) both proteins are stress-inducible; (2) both are involved at the site of DNA repair; each protein seems to be recruited to the damaged DNA region and interact with the components of DNA repair particles; and (3) the two proteins can act on the regulation of a single gene. In the present study, we present evidence that YB-1 interacts with p53, and this interaction mutually modulates the DNA binding activity of these proteins.
Results
YB-1 interacts with p53 in vitro and in vivo p53 is a nuclear protein that is normally expressed at low levels, but is rapidly up-regulated when cells are treated with various DNA damaging agents, including the anticancer drug, cisplatin. When KB epidermoid cancer cells were treated with cisplatin for 12 h, nuclear levels of p53 increased ®ve-fold compared to untreated KB cells (Figure 1a) . Using a GST-fusion protein expression plasmid for YB-1, we previously showed that YB-1 binds preferentially to cisplatin modi®ed DNA (Ise et al., 1999) . We therefore utilized a GST pull-down assay to determine whether p53 can interact with a GST-YB-1 fusion protein. We found that p53 interacts with YB-1, a result that was con®rmed by a reciprocal p53 pull-down assay (Figure 1b) .
To determine whether YB-1 can interact with p53 in vivo, nuclear extracts of cells incubated in the presence or absence of cisplatin were reacted with a speci®c antibody against p53, and the protein complexes were examined by sequential immunoprecipitation and immunoblotting ( Figure 1c ). YB-1 was co-precipitated by antibody to p53 but not by the control antibody.
p53 binding domain in YB-1
To determine whether YB-1 can directly interact with p53, and to identify the p53 binding region in YB-1, we performed pull-down assays using a recombinant ThioHis-p53 fusion protein and GST fusion proteins containing either full-length YB-1 or mutant derivatives, GST-YB-1D1*D5 (Figure 2a ). ThioHis-p53 bound to GST-YB-1, GST-YB-1D1, D2, D3, D4, but not to GST-YB-1D5 (Figure 2b ). (a) Nuclear accumulation of p53 induced by cisplatin. The nuclear fraction, cytosol fraction, and whole cell extract were prepared from KB cells incubated for 12 h in the presence or absence of cisplatin (CDDP). Proteins were fractionated on a 10% SDS ± PAGE gel and transferred to a PVDF membrane. The membrane was incubated with anti-p53 Ab, Do-1, followed by horseradish peroxidase-conjugated secondary Ab. (b) Nuclear extract (NE) from cisplatin-treated KB cells was applied to a GST or GST-YB-1 anity column (upper panel), and the pull-down assay was performed as described in Materials and methods. The bound proteins and 1% of the starting material were analysed by Western blot analysis with Do-1. A reciprocal assay was performed with a GST or GST-p53 anity column (lower panel) and an anti-YB-1 Ab. (c) Nuclear extract prepared as described in (a) was immunoprecipitated with Do-1, and the resulting immunocomplex was subjected to SDS ± PAGE and analysed by Western blotting with an anti-YB-1 Ab To assess the interaction site of YB-1 in greater detail, we synthesized GST-YB-1 fusion proteins containing additional deletions in the C-terminal region, GST-YB-1D6*D10 (Figure 3a,b) , and assayed the ability of these proteins to bind endogenous p53 of cisplatin-treated cells. We found that endogenous p53 bound to GST-YB-1, GST-YB-1D6, D7, D8, D9, but not to GST-YB-1D10 (Figure 3c ). These ®ndings suggest that three independent sites in YB-1, an Nterminal domain located at amino acids 1 ± 51 and two C-terminal regions located at amino acids 129 ± 205 and 272 ± 324, are involved in complex formation with p53.
YB-1 binding domain in p53
We also determined the regions in p53 that interact with YB-1. GST-fused p53 derivatives ( Figure 4a ) were puri®ed on glutathione-Sepharose 4B anity columns and detected by Coomassie blue in SDS ± PAGE ( Figure 4b ). The ThioHis-YB-1 fusion protein was subsequently subjected to anity chromatography on columns containing GST-p53 derivatives. These pulldown assays demonstrated that the ThioHis-YB-1 fusion protein bound residues 347 to 393 in the Cterminal region of p53 (Figure 4c).
To assess the interaction site of p53 in greater detail, we synthesized ThioHis-p53 fusion proteins containing additional deletions in the C-terminal region and assayed the ability of these proteins to bind GST-YB-1 (Figure 5a ,b). We found that fusion proteins of fulllength p53 and p53 N376, containing amino acid residues 1 to 376, bound to YB-1, whereas p53 N362, containing amino acid residues 1 to 362, did not. These ®ndings suggest that the YB-1 binding region of p53 is located in the region from residue 363 to 376.
Binding of p53 to its specific consensus sequences
Previous studies indicated that the basic carboxy terminus of p53 negatively regulates sequence-speci®c DNA binding activity of the p53 core-domain, and manipulation of this region relieves the suppression and activates DNA binding activity. Since the YB-1 binding domain in p53 is localized in this carboxyregulatory domain, we hypothesized that YB-1 may in¯uence sequence-speci®c DNA binding activity. We performed electrophoretic mobility shift assays (EMSA) using puri®ed GST-fusion proteins and a double stranded oligonucleotide containing a p53 consensus sequence ( Figure 6 ). Sequence-speci®c DNA binding activity of the full-length p53 was stimulated in the presence of PAb421, an anti-p53 monoclonal antibody. When YB-1 protein was prereacted in the reaction mixture, DNA binding of p53 was markedly increased. Surprisingly, however, no further retardation of the mobility of the p53-DNA complex was seen. (Ise et al., 1999) . CSD indicates the cold shock domain. (b) Interaction of GST-YB-1 deletion mutants with ThioHis-p53. Approximately 1 mg of each GST fusion protein was immobilized on 15 ml glutathione-Sepharose 4B, and the resin was incubated with a 100-fold excess of ThioHis-p53. Proteins bound to the resin were analysed by Western blot using an anti-Thio Ab The deletion mutants were expressed in bacteria, puri®ed on 15 ml glutathione-Sepharose 4B, and analysed by Coomassie blue staining of SDS ± PAGE. *Fulllength GST fusion proteins. (c) Interaction of GST-YB-1 deletion mutants with endogenous p53. The resin on which each GST fusion protein was immobilized was incubated with 500 mg of CDDP-treated total cell extract. Proteins bound to the resin were analysed by Western blot using an anti-p53 Ab, Do-1
Binding of YB-1 to its specific consensus sequences YB-1 is a multifunctional factor that can bind to double-stranded and single-stranded DNA, and RNA. We previously demonstrated that YB-1 is involved in the Y-box dependent transactivation of the MDR1 gene and in the complex which binds to duplex Y-box sequences . Our results on the interaction between YB-1 and p53 prompted us to examine the eect of p53 on the Y-box binding activity of YB-1. We performed EMSA using puri®ed GST-fusion proteins and a double-stranded Y-box element (Figure 7 ). Recombinant YB-1 clearly bound to double stranded Y-box elements, a binding that was decreased by wild-type p53 protein, but not by control GST protein (A) or mutant type p53 protein (B). Inclusion of unlabeled Y-box oligonucleotide as a speci®c competitor or p53 consensus sequence oligonucleotide as a nonspeci®c competitor indicated the speci®city of YB-1 binding to the Y-box sequence. YB-1 also bound to nonspeci®c DNA with moderate anity. Schematic illustration of the GST-p53 deletion mutants used. An N-number indicates that the recombinant protein begins at amino acid 1 and extends to the indicated residue, and the number-C indicates that the recombinant protein begins at that amino acid and extends to the C-terminus. (b) Puri®cation of recombinant proteins. Deletion mutants were expressed in bacteria, puri®ed on 15 ml glutathione-Sepharose 4B and analysed by Coomassie blue staining of SDS ± PAGE. (c) Interaction of GST-p53 deletion mutants with ThioHis-YB-1. Each GST fusion protein was immobilized on 15 ml glutathione-Sepharose 4B, and the resin was incubated with a 75-fold excess of ThioHis-YB-1. Proteins bound to the resin were analysed by Western blot using an antiThio Ab Previous research has demonstrated that a wild-type p53 down-regulates expression from the MDR1 promoter, while a mutant p53 does not (Chin et al., 1992; Thottassery et al., 1997) . To determine whether a Y-box element is involved in the inhibition of MDR1 promoter activity by p53, PC3 cells were transfected with luciferase reporter plasmids, bearing an MDR1 promoter with or without a mutation in the Y-box, along with wild-type p53 expression plasmid (Figure 8 , left panel). Mutation in the Y-box reduced MDR1 promoter activity to 60%. Cotransfection of wild-type p53 expression plasmid signi®cantly decreased the reporter activity of pMDR-luc, the plasmid bearing unmutated Y box, but had no eect on the luciferase activity of pMDR-Ym-luc, the plasmid bearing a mutation in the Y-box. We also found that mutant p53 had no eect on the MDR1 promoter activity (data not shown). These data indicate that p53 downregulates MDR1 gene expression through interaction with YB-1.
We next assessed the eect of YB-1 on the transactivation ability of p53 (Figure 8, right panel) . Overexpression method was not always successful because YB-1 is mainly localized in the cytoplasm (Koike et al., 1997) . We previously used antisense expression plasmid and showed that this antisense plasmid works well in cancer cells . We then introduced a luciferase reporter plasmid, p21-luc, carrying a p21 promoter to the PC3 cells, along with YB-1 antisense expression plasmid, AS 0.7 YB-1, and wild-type p53 expression plasmid. Cotransfection of YB-1 antisense plasmid decreased the p53-activated promoter activity of p21-luc, thus suggesting that YB-1 protein in¯uences the p53 function of transcriptional regulation.
Discussion
Protein ± protein interactions are critical for biologic function. p53 is a multifunctional protein which interacts with a variety of proteins to yield functionally positive and negative in¯uences. We demonstrated here that YB-1 protein directly associates with p53 in vivo and in vitro. Although YB-1 was ®rst identi®ed as a cellular transcriptional factor, it has recently been shown to be multifunctional, regulating gene expression on both transcriptional and translational levels. Thus, the interaction of the two proteins may in¯uence multiple functions of each protein.
EMSA assays with puri®ed recombinant proteins demonstrated that YB-1 activates the binding activity of p53 to its consensus sequence. It has been shown that p53 is phosphorylated, dephosphorylated, or acetylated in response to DNA damage, thus altering the conformation and the activity of this protein (Canman et al., 1998; Banin et al., 1998; Kapoor and Lozano, 1998; Waterman et al., 1998; Sakaguchi et al., 1998; Gu and Roeder, 1997) . In addition, the sequence-speci®c DNA binding function of p53 has been shown to be activated through its modi®cations of the C-terminal negative regulatory domain, by either PAb421 or small peptides (Halazonetis et al., 1993; Hupp et al., 1995) , as well as CKII or P300 (Kapoor and Lozano, 1998; Gu and Roeder, 1997) . Since the YB-1 binding site within p53 is located in the Cterminal negative regulatory domain, YB-1 may have an in¯uence on the modi®cations of p53 and the resulting conformational change to an activated form. We initially considered that the complex of p53 with YB-1 makes a ternary complex with double-stranded DNA; however, in this present experiment, YB-1 does not alter the electrophoretic mobility of p53 complexed with oligonucleotides and only stimulates DNA binding activity of p53. Interestingly, a recent study from Jayaraman et al. (1998) demonstrated that HMG1, known as a single-strand DNA binding protein, directly interacts with p53 and activates sequence-speci®c DNA binding activity of p53. HMG1/2 is a nonhistone chromosomal protein which recognize a variety of DNA structures. YB-1 is also a single-strand DNA binding protein and, in that way, has a similar function as HMG1. HMG1, like YB-1 in the present experiment, stimulates DNA binding activity of p53, but does not alter the electrophoretic mobility of p53 complexed with oligonucleotides. The interaction of p53 with HMG1 is thought to be transient, and HMG1 dissociates from the complex before gel electrophoresis; we believe that the present study makes the same case. It is possible that YB-1, by binding to the p53 C-terminus, may only modulate Cterminal regulatory function, and may separate from p53 in the process of binding to double-stranded DNA.
YB-1 was initially identi®ed as a transcriptional regulator that recognizes speci®c cis-elements, the inverted CCAAT box or Y-box. Recently, the biological function of Y-box proteins as regulators of gene expression, including translational regulation, has been revealed; however, the mechanism by which Ybox proteins modulate transcription is still poorly understood. To analyse the functional mechanisms of this protein, investigating partner proteins which associate with YB-1 is critical. Recent studies revealed that YB-1 associates with RelA, YY-1 and Pura to modulate gene expression (Raj et al., 1996; Li et al., 1997; Safak et al., 1999) . We now show that wild-type p53 interacts with YB-1 and inhibits the sequence speci®c DNA binding activity of YB-1. To clarify the biological signi®cance of this interaction in the regulation of gene expression, we performed transient transfection assays using speci®c YB-1-or p53-target gene promoter-reporter constructs. As demonstrated in Figure 8 , the promoter activity of MDR1 gene was markedly down-regulated by introduction of wild-type p53 but not by introduction of mutant type p53. Further, p53-activated promoter activity of p21 is reduced by cotransfection of YB-1 antisense expression plasmid. These views are compatible with the results obtained in EMSA.
YB-1 protein has three independent domains; an amino-terminal region (aa 1*50), a cold shock domain (aa 51*129) and a carboxy-tail region (aa 130*C-terminus). The central cold shock domain is a highly conserved nucleic acid recognition domain, containing RNP-like motifs. The C-tail domain consists of alternating positively and negatively charged regions, called charged zipper domains, and is thought to interact with other cellular proteins or nucleic acids (Wole, 1994) . The present study demonstrates that YB-1 can bind to p53 through its three independent domains. Two domains are localized to amino acids 129 to 205 and 272 to 324 of the C-tail domain. These two regions contain a part of the charged zipper which consists of highly acidic and basic charged areas. The other binding region is located at the N-terminal region, amino acids 1 to 51. This site is rich in proline and alanine and seems to be critical for transcriptional regulation; thus, p53 binding activity of this region was unexpected. However, the most N-terminal region of YB-1 is highly acidic. On the other hand, the region between aa 363 ± 376 of p53 is highly basic, suggesting that this charged area may facilitate the interaction with the acidic region of YB-1. Ruzanov et al. (1999) reported that the rabbit Y-box protein, p50, interacts with actin through an actin-binding site in the N-terminus. The conformation of the YB-1-p53 complex is unclear; however, p53 binding sites in YB-1 are numerous, and p53 may conceal nucleic acid binding sites of YB-1. Interaction through oligomerization and conformational changes of the two proteins should be investigated further.
One model of induction of p53 activity after DNA damage is as follows (Gottlieb and Oren, 1996) : when DNA damage creates single-stranded regions, DNA ends, and insertion/deletion mismatches, the p53 protein is recruited to the damaged DNA region via high binding anity of its C-terminus for these structures, interaction with other repair associated proteins, such as RPA, XPB, and XPD, also cause p53 accumulation. Sequence speci®c DNA binding activity is then stimulated by short, single-stranded DNA produced in process of NER or by other modi®cation of the C-terminal regulatory domain. YB-1 also accumulates in the nucleus under genotoxic stress (Koike et al., 1997) and preferably associates with single-stranded, apurinic, or cisplatin-adducted DNA; thus, it is possible that YB-1 interacts with p53, as well as with PCNA, in the DNA damage region to function in the DNA repair machinery and to subsequently activate speci®c DNA binding activity of p53.
Our results demonstrate that YB-1 directly interacts with p53, and this interaction reciprocally modulates the DNA binding function of each protein. The mutual interaction of p53 and YB-1 also modulates expression of human genes containing p53 or YB-1 binding sites. The biological signi®cance of this complex requires additional in-depth investigation.
Materials and methods

Plasmids
Construction of p53 expression plasmids: total RNA was extracted from KB human epidermoid cancer cells containing wild-type p53, and from the human colon cancer, KM12C cells containing a mutant p53 (His to Arg mutation at amino acid 179). Following synthesis of cDNA, full-length human p53 cDNA was ampli®ed using the primer pairs, 5'-CCATGGAGGAGCCGCAGTCA-GATCC-3', and 5'-GAAGTGGAGAATGTCAGTCTGAG-TCAGG'. The PCR product was cloned into pGEM-T Easy (Promega, Madison, WI, USA). Plasmid DNA was puri®ed and digested with NotI and each full-length p53 cDNA was cloned into pGEX-4T (Pharmacia Biotech. Inc., Tokyo, Japan) and pThioHis (Invitrogen, Groningen, Netherlands) for expression in bacteria. The plasmids containing full-length GST-YB-1 cDNA, ®ve GST-YB-1 deletion mutants (GST-YB-1D1, D2, D3, D4 and D5) and ThioHis-YB-1 have been described previously (Ise et al., 1999) . To construct GST-YB-1 D6, GST-YB-1 D3 was digested with NotI and EcoT141, the 3' overhangs were ®lled in with T4 DNA polymerase (Takara Shuzo, Tokyo, Japan) and the DNA fragment was then ligated. To construct GST-YB-1 D7, GST-YB-1 D3 was digested with SalI, and the DNA fragment was then self-ligated. To construct GST-YB-1 D8, the SalI fragment was ligated to the pGEX4T vector. To construct GST-YB-1 D9, GST-YB-1 D8 was digested with EcoT141 and SmaI, and self-ligated after ®lling in with T4 DNA polymerase. To construct GST-YB-1 D10, GST-YB-1 D8 was digested with NotI and EcoT141.
GST-p53 deletion mutants: to construct GST-p53 N346, the GST-p53 full-length expression plasmid was digested with SalI and StuI, the 5' overhangs were ®lled in with Klenow fragment (Takara Shuzo), and the DNA was then ligated and transformed. GST-p53 N180 was constructed by digesting the GST-p53 plasmid with Eco47III and SmaI, GST-p53 N124 was constructed by digesting GST-p53 with BsaAI, and GSTp53 160C was constructed by digesting GST-p53 with NcoI. GST-p53 160 ± 346 plasmid was prepared from GST-p53 N346 by NcoI digestion and self-ligation. ThioHisp53 deletion mutants were constructed from the ThioHis-p53 full-length plasmid by digestion with AccI for N376, BarII for N362, P¯MI for N322, NcoI for 160C, and Eco811 for 224C.
MDR-luc plasmid utilized for the luciferase assay, was prepared by digesting the pMDRCAT7 plasmid with XhoI and HindIII and ligating the nt7136 to nt +121 fragment of the MDR1 promoter into the XhoI and HindIII sites of pGL2-basic vector (Promega). To construct MDR-Ym-luc plasmids; site-directed mutagenesis of the Ybox in the MDR1 promoter was introduced by a PCRbased method (Furukawa et al., 1998) using the primer, 5'-CCCAGTTGATCAGCCTCACC-3'. A p21 promoter (nt 72340 to nt +75) construct was cloned from human placenta genomic DNA by a PCR method using the primers, 5'-CTTCCCAGGAACATGCTTGGG-3', and 5'-CTCACCTCCTCTGAGTGCCTCGG-3', and ligating the cloned DNA into the pGL2 vector. YB-1 antisense expression plasmid, AS 0.7 YB-1, was described previously .
Antibodies
Antibodies to p53, Do-1, and PAb421 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and CALBIOCHEM (San Diego, CA, USA), respectively. Antibody to YB-1 was generated as described previously (Ohga et al., 1996) . Antibodies to ThioHis-fusion proteins were purchased from Invitrogen.
Cell lines
KB human epidermoid cancer cells were grown in modi®ed Eagle's medium supplemented with 10% newborn bovine serum and antibiotics. p53-null PC3 human prostate cancer cells were grown in modi®ed Eagle's medium supplemented with 10% fetal bovine serum and antibiotics.
Protein pull-down assay using GST fusion proteins KB cells were incubated in the presence or absence of cisplatin (10 mM) for 12 h, and nuclear extracts were prepared as described (Furukawa et al., 1998) . Each extract was dialyzed against buer A [20 mM Tris-HCl (pH 8.0), 0.5 mM EDTA, 20% glycerol, 1 mM DTT, 1 mM phenylmethylsulfonyl¯uoride (PMSF)], also containing 0.5 M KCl. Recombinant GST-fusion proteins expressed in bacteria were prepared in Pull Down (PD) Buer [50 mM Tris-HCl (pH 8.0), 0.5 mM EDTA, 0.1 mM EGTA, 10% glycerol, 1 mM DTT, 0.5 mM PMSF], supplemented with 0.2 M KCl. Anity columns were prepared by immobilizing GST or GST fusion proteins on glutathione-Sepharose 4B (Pharmacia). Each KB nuclear extract was loaded onto 20 ml of anity resin and incubated for 1 h at 48C. After washing the column ®ve times with 1 ml of buer A, also containing 100 mM KCl and 0.1% Nonidet P40, the column resin was boiled in Western sample buer. Column eluates and starting material were subjected to SDS ± PAGE.
For GST pull-down assays against ThioHis fusion protein, GST and ThioHis fusion protein expression in bacteria was induced by incubation with 1 mM isopropyl-D-thiogalactopyranoside (IPTG), at an optical density of 0.6 to 0.8, for 1 to 2 h at room temperature. Cells were collected by centrifugation and sonicated in 300 ml of Binding Buer [50 mM Tris-HCl (pH 8.0), 1 mM EDTA, 10% glycerol, 0.5% Nonidet P40, 1 mM DTT, 0.5 mM PMSF]. The cell lysates were cleared by centrifugation, and the supernatants were screened by Western blot analysis using antibodies directed against GST and Thio. ThioHis fusion proteins were loaded onto 15 ml of anity resin containing GST fusion proteins and incubated for 1 h at 48C. After washing the resin three times with 1 ml of binding buer, the column resin was boiled in Western sample buer. Column eluates and starting material were subjected to SDS ± PAGE. Proteins contained in the binding complex were detected by immunoblot analysis with anti-Thio antibody.
Coimmunoprecipitation assay
Each nuclear extract was incubated for 1 h at 48C with antip53 antibody (Do-1) in NET-gel buer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 0.25% gelatin, 0.02% sodium azide, 1 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin], and then with Protein A-Sepharose (Pharmacia) for 1 h at 48C. The beads were washed twice with NET-gel buer and once with 10 mM Tris-HCl (pH 7.5) 0.1% NP40. After centrifugation, the precipitate and starting material were boiled in Western sample buer for SDS ± PAGE and Western blot analysis.
Emsa
Sequences of the oligonucleotides used as probes were as follows: MDR Y-box, 5'-GGTGAGGCTGATTGGCTGGG-CAGGA-3', p53 consensus, 5'-TCAGGAACATGTCCCAA-CATGTTGAGCT-3'. Double-stranded oligonucleotides were labeled with g-32 P using T4 polynucleotide kinase and puri®ed on PAGE gels. After puri®cation of GST-fusion proteins, using glutathione-Sepharose 4B and GST elution buer [100 mM Tris-HCl (pH 8.0), 20 mM reduced glutathione, 120 mM NaCl], the identity of each fusion protein was veri®ed by Coomassie blue staining of 10% SDS ± PAGE gels, and the concentration of each protein was equalized with GST elution buer. EMSA was performed as described previously (Furukawa et al., 1998) .
Transfection
For transient transfection, PC3 cells were plated at a density of 5610 4 cells/well the day before transfection. At approximately 50% con¯uence, the cells were co-transfected with 0.2 mg of reporter plasmid, 0.6 mg of expression plasmid and 0.2 mg of pCH110 using 2 ml of SuperFect according to the protocol (QIAGEN, Germany). Three hours later, cells were washed twice with PBS and changed to the fresh medium. Twenty-four hours post-transfection, luciferase activity was measured as described below. In case of using antisense plasmid, 1.0 mg of YB-1 antisense expression plasmid or vector plasmid was transfected 24 h prior to ®rst transfection.
Luciferase assay
Luciferase activity of transient transfectants was measured using the Luciferase assay protocol (Promega). Brie¯y transfected cells were lysed in 200 ml 16Passive Lysis Buer, and the lysates were subjected to a freeze/thaw cycle. After centrifugation, 20 ml of each supernatant was assayed for luciferase activity. To standardize the luciferase activity, transfection eciency was calculated by b-galactosidase activity.
Statistical analysis
The statistical signi®cance of the luciferase assay was determined by Student's t-test using SAS software (SAS Institute, Tokyo, Japan). Signi®cance was set at the 5% level.
